Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START SYNERGY
2025-524005-32-00Phase 2Authorised
- Sponsor
- Elevara Medicines
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of ELV001 in rheumatoid arthritis (RA) (4 arms), sponsored by Elevara Medicines. Primary endpoint: Change in DAS28-CRP from baseline to Week 12. Planned start May 2026; status: authorised.
02
Drugs
ELV001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2025-524005-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524005-32-00.